Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics, Inc.

SAN FRANCISCO AND BOSTON, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE STIFEL 2025 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM ON TUESDAY, SEPTEMBER 16, 2025, AT 11:30 A.M. E.T.

APOGEE THERAPEUTICS TO PARTICIPATE AT THE STIFEL 2025 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM

POSITIVE 16-WEEK DATA FROM APEX PHASE 2 PART A MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS FOR APG777, A POTENTIALLY BEST-IN-CLASS ANTI-IL-13 ANTIBODY, IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

APEX PART A MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS AND EXCEEDED TRIAL OBJECTIVES, INCLUDING 7 1.0% DECREASE FROM BASELINE IN EASI AT WEEK 16

APOGEE THERAPEUTICS ANNOUNCES POSITIVE 16-WEEK DATA FROM PHASE 2 APEX CLINICAL TRIAL OF APG777, ITS POTENTIALLY BEST-IN-CLASS ANTI-IL-13 ANTIBODY, IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

SAN FRANCISCO AND BOSTON, JULY 06, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING NOVEL BIOLOGICS WITH THE POTENTIAL FOR DIFFERENTIATED EFFICACY AND DOSING IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, INCLUDING FOR THE TREATMENT OF ATOPIC DERMATITIS (AD), ASTHMA, EOSINOPHILIC ESOPHAGITIS (EOE), CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND OTHER I&I INDICATIONS, TODAY ANNOUNCED IT WILL REPORT PART A 16-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF APG777 ON MONDAY, JULY 7, 2025. FOLLOWING THE ANNOUNCEMENT, THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:00 A.M.

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT PART A 16-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF APG777 IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS ON JULY 7, 2025

SAN FRANCISCO AND BOSTON, MAY 29, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON THURSDAY, JUNE 5, 2025, AT 10:30 A.M. E.T.

APOGEE THERAPEUTICS TO PARTICIPATE AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

PHASE 2 APEX TRIAL OF APG777 IN ATOPIC DERMATITIS ADVANCING WITH INTERIM PART A 16-WEEK DATA EXPECTED IN MID-2025 AND PART B ACTIVELY ENROLLING

APOGEE THERAPEUTICS PROVIDES BUSINESS UPDATE, PIPELINE PROGRESS AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

MULTIPLE DOSES OF APG808 RESULTED IN RAPID SUPPRESSION OF FENO, A BIOMARKER OF TYPE 2 INFLAMMATION ASSOCIATED WITH EXACERBATIONS IN ASTHMA, WITH A ROBUST MAXIMAL FENO DECREASE FROM BASELINE OF 53%

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM THE PHASE 1B TRIAL OF APG808, ITS NOVEL HALF-LIFE EXTENDED IL-4R ANTIBODY, IN PATIENTS WITH MILD-TO-MODERATE ASTHMA

SAN FRANCISCO AND BOSTON, MAY 01, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PRESENT AT THE BANK OF AMERICA HEALTH CARE CONFERENCE ON TUESDAY, MAY 13, 2025, AT 1:40 P.M. P.T. / 4:40 P.M. E.T.

APOGEE THERAPEUTICS TO PARTICIPATE AT THE BANK OF AMERICA 2025 HEALTH CARE CONFERENCE

ACCELERATED EXECUTION OF PHASE 2 APEX CLINICAL TRIAL FOR APG777, WITH PART A OVER-ENROLLED AND PART B INITIATED AHEAD OF SCHEDULE; TOPLINE PART A 16-WEEK DATA EXPECTED MID-2025

APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS FULL YEAR 2024 FINANCIAL RESULTS

INTERIM PHASE 1 RESULTS FOR APG990, A NOVEL HALF-LIFE EXTENDED OX40L ANTIBODY, EXCEEDED TRIAL OBJECTIVES AND DEMONSTRATED AN APPROXIMATELY 60-DAY HALF-LIFE

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 RESULTS FROM THE APG990 HEALTHY VOLUNTEER TRIAL, UNLOCKING POTENTIAL MAINTENANCE DOSING EVERY THREE AND SIX MONTHS FOR APG279 (APG777 + APG990)

SAN FRANCISCO AND BOSTON, FEB. 28, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING NOVEL BIOLOGICS WITH POTENTIAL FOR DIFFERENTIATED EFFICACY AND DOSING IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, INCLUDING FOR THE TREATMENT OF ATOPIC DERMATITIS (AD), ASTHMA, EOSINOPHILIC ESOPHAGITIS (EOE), CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND OTHER I&I INDICATIONS, TODAY ANNOUNCED IT WILL REPORT INTERIM RESULTS FROM THE PHASE 1 APG990 HEALTHY VOLUNTEER TRIAL ON MONDAY, MARCH 3, 2025. FOLLOWING THE ANNOUNCEMENT, THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:30AM ET TO DISCUSS THE RESULTS AND PLANS FOR ITS COMBINATION APPROACH FOR APG777 + APG990.

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT INTERIM RESULTS FROM THE PHASE 1 HEALTHY VOLUNTEER TRIAL FOR APG990 AND PROVIDE COMBINATION STRATEGY UPDATE ON MARCH 3, 2025

Apogee Therapeutics, Inc.

APGE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Apogee Therapeutics, Inc.

APGE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

APGE